Ozempic - What it is and Isn't

Ozempic® is the brand name for semaglutide, a once-weekly GLP-1 receptor agonist injection. It mimics the gut hormone GLP-1, helping the pancreas release insulin when glucose is high, reducing glucagon, slowing stomach emptying, and increasing satiety. In the U.S., Ozempic is approved for adults with type 2 diabetes to improve A1C and to lower the risk of major cardiovascular events in those with established cardiovascular disease. As of a January 2025 label update, Ozempic is also indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Ozempic is not FDA-approved for weight loss (that indication belongs to the higher-dose semaglutide brand Wegovy®).

GLP-1 medicines emerged from decades of research linking incretin hormones to glucose control. Semaglutide was developed by Novo Nordisk and Ozempic was first FDA-approved in 2017 for type 2 diabetes, with cardiovascular-risk reduction later added based on outcomes data (SUSTAIN-6). In 2025, kidney-outcomes data (FLOW) led to the new chronic-kidney-disease indication.

• Ozempic (semaglutide):
  • Adjunct to diet & exercise to improve glycemic control in adults with type 2 diabetes.
  • Reduce MACE (CV death, non-fatal MI, non-fatal stroke) in adults with T2D and established CVD.
  • Reduce risk of sustained eGFR decline, ESKD, and CV death in adults with T2D and CKD.
  • Not approved for weight loss.

• Wegovy (semaglutide 2.4 mg):
  • FDA-approved for chronic weight management.
  • March 8, 2024: first obesity medicine approved to reduce risk of CV death, heart attack, and stroke in adults with CVD and obesity/overweight.

• Rybelsus (oral semaglutide):
  • Once-daily tablet version of semaglutide approved for adults with type 2 diabetes to improve glycemic control (not weight management). Recent label updates describe two formulations with dose-escalation schemes.

Across pivotal trials, weekly semaglutide typically lowers A1C by ~1.2%–1.7%, with ~66–73% of patients reaching A1C <7% depending on dose and background therapy. In a representative 30-week study, A1C fell −1.3% to −1.7% with 0.5–1 mg; 70–73% achieved <7%.

Although not a weight-loss drug, Ozempic consistently produces modest weight reduction in T2D. In placebo-controlled data, mean losses were about −3.8 kg to −4.7 kg at 30 weeks (0.5–1 mg). A broader SUSTAIN analysis found ≥5% weight loss in ~30%–68% of participants across doses/comparators.

In patients with T2D and established CVD, semaglutide reduces major adverse CV events versus placebo (SUSTAIN-6), underpinning the FDA CV indication on the Ozempic label.

New in 2025: Ozempic is indicated to reduce risk of sustained eGFR decline, ESKD, and CV death in adults with T2D and CKD, reflecting kidney-outcomes data (FLOW).

Gastrointestinal effects are the most common (nausea, vomiting, diarrhea, constipation, abdominal pain). In pooled trials, GI events occurred in ~33%–36% on semaglutide vs ~15% on placebo; 3%–4% discontinued for GI reasons. Ileus (intestinal blockage) appears in post-marketing reports.

Other important warnings on the Ozempic label include:

• Boxed warning for thyroid C-cell tumors (rodent data); contraindicated with personal/family history of medullary thyroid carcinoma (MTC) or MEN 2.

• Acute pancreatitis; stop if suspected.

• Diabetic retinopathy complications—monitor patients with existing DR.

• Gallbladder events (cholelithiasis/cholecystitis) and acute kidney injury (often with dehydration from GI losses).

• Hypoglycemia risk increases when combined with insulin or sulfonylureas.

• Delayed gastric emptying: newly formalized caution about pulmonary aspiration during anesthesia or deep sedation; some patients may need fasting adjustments or temporary holds before procedures.

A multi-society anesthesia statement in 2024 advised that most patients can continue GLP-1s before elective surgery, with risk-mitigation (e.g., 24-hour liquid diet) for those at higher GI risk. Follow your surgical team’s instructions.

• Do not use if you or a family member has MTC or you have MEN 2.

• Pregnancy: discuss plans; the label advises stopping at least 2 months before a planned pregnancy because of the long washout. Limited lactation data.

• Severe gastroparesis: Ozempic is not recommended.

• Pediatrics: safety/efficacy not established for Ozempic in children. (Wegovy carries pediatric obesity indications; Ozempic does not.)

• Compounded semaglutide: professional groups advise avoiding non-FDA-approved compounded GLP-1s given safety/quality concerns.

Ozempic is approved for adults; trial populations spanned a wide adult age range with benefits seen across ages. Subgroup analyses across SUSTAIN/PIONEER programs show consistent A1C and weight effects across sex, without clinically meaningful efficacy differences between men and women. Real-world prescribing patterns vary by setting, but efficacy signals are broadly similar. 

• Intolerance: A minority stop treatment due to GI side effects (≈3–4%). Slow, stepwise dose escalation helps.

• Weight regain after stopping: Discontinuation commonly leads to regain of a substantial portion of lost weight within ~1 year, underscoring the need for ongoing treatment and lifestyle support when weight loss is the goal.

• Under-dosing or rushed escalation can impair results; titration should follow the label.

Consider Ozempic if you are an adult with type 2 diabetes who:

• Needs additional A1C lowering beyond lifestyle and first-line therapies.

• Has established cardiovascular disease—to reduce MACE.

• Has chronic kidney disease—to reduce sustained eGFR decline, ESKD, and CV death risks.
  These align with both the FDA label and diabetes-care guidelines prioritizing GLP-1 RAs for patients with T2D plus ASCVD/CKD and for those who would benefit from weight-supportive glucose agents. (See ADA Standards of Care.) 

If your sole goal is weight loss without diabetes, talk with your clinician about Wegovy (semaglutide 2.4 mg) or other FDA-approved anti-obesity medications; using Ozempic for weight loss is off-label.

• Oral semaglutide (Rybelsus)—a tablet GLP-1 RA for adults with T2D (not weight management).

• Other classes: metformin, SGLT2 inhibitors, DPP-4 inhibitors, basal insulin, and more—your clinician can tailor a regimen per comorbidities and A1C goals (see ADA SOC). 

• FDA-approved, long-term anti-obesity meds include orlistat, phentermine/topiramate ER, naltrexone/bupropion SR, liraglutide, semaglutide 2.4 mg (Wegovy), and tirzepatide (Zepbound); eligibility usually requires BMI criteria plus lifestyle therapy.

• Device (non-drug) option: Plenity®—a prescription, ingested hydrogel that increases fullness; FDA De Novo-cleared for adults with BMI 25–40 when used with diet and exercise. (A pill, not a hormone-based medication.)

• Procedural options: metabolic/bariatric surgery and endoscopic sleeve gastroplasty for appropriate candidates.

Regulators are now reviewing an oral Wegovy formulation; late-stage oral GLP-1 programs (from several companies) suggest ~12%–15% average weight loss in trials, with first approvals possible in late 2025–2026. Expect oral options to expand rapidly.

1. History/risks: rule out MTC/MEN2; review pancreatitis, gallbladder disease, retinopathy, kidney function, and severe GI disorders.

2. Med list: consider reducing doses of insulin or sulfonylureas to limit hypoglycemia.

3. Surgery coming up? Discuss anesthesia plans due to delayed gastric emptying. 

4. Pregnancy planning: discontinue ≥2 months before trying to conceive.

5. Avoid non-FDA-approved compounded products.

• Dosing: start at 0.25 mg weekly, step up to 0.5 mg, then 1 mg, and—if needed for glycemic control—2 mg, each step typically after ≥4 weeks. Slower titration improves tolerability.

• Side effects: expect transient nausea, fullness, and/or GI upset, especially during dose increases; careful hydration and smaller, lower-fat meals help.

• Monitoring: A1C, glucose (particularly if on insulin/sulfonylurea), weight, kidney function, and eye status if you have retinopathy.

The obesity-care market is scaling fast, with analysts projecting >$150 billion annually by the early 2030s as access, formulations (including oral GLP-1s), and real-world outcomes evolve. Expect broader use in cardiometabolic disease beyond glucose control, alongside payer and policy shifts.

• Use Ozempic if you have type 2 diabetes and need better A1C control—especially with established CVD or CKD, where it has proven outcome benefits. It also tends to reduce weight modestly in people with T2D.

• Weight loss without diabetes, consider Wegovy or other FDA-approved anti-obesity options, or procedures, based on your clinical profile. Expect to maintain therapy (plus lifestyle changes) to maintain results.